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Synopses
Campylobacter jejuni subsp. jejuni (C. jejuni)
and C. coli have been recognized since the late
1970s as important agents of gastrointestinal
infections throughout the world; in the United
States, these infections affect approximately 1%
of the population each year (1). Contaminated
food is the usual source of human infections;
therefore, the presence of fluoroquinolone- and
macrolide-resistant strains in the food chain has
raised concerns that the treatment of human
infections will be compromised. Most cases of
Campylobacter enteritis do not require antimi-
crobial treatment, being brief, clinically mild, and
self-limiting (2-4). However, a substantial propor-
tion of these infections require treatment. These
include severe and prolonged cases of enteritis,
septicemia, and other extraintestinal infections.
Erythromycin has been the most commonly used
agent for treating Campylobacter enteritis (2,5).
In the 1980s, the introduction of fluoroquino-
lones, which are effective against most major
pathogens causing bacterial enteritis, offered a
new approach to antibiotic intervention (6).
Fluoroquinolones initially had good in vitro
activity for thermophilic Campylobacter species,
as well as for members of the family of
Enterobacteriaceae.
Early clinical trials of both community-
acquired acute diarrhea and traveler’s diarrhea
caused by Campylobacter demonstrated that
patients treated with a fluoroquinolone had  good
clinical response (6,7). It soon became apparent,
however, that resistance in Campylobacter spp.
could arise in vivo, sometimes after only one or
two administrations of fluoroquinolones (8).
Moreover, Endtz and colleagues (9) reported as
early as 1991 that the emergence of quinolone-
resistant  C. jejuni and C. coli isolated from
humans in the Netherlands coincided with the
introduction of fluoroquinolones in veterinary
medicine.
Fluoroquinolone resistance in Campylo-
bacter from food animals is now recognized as an
emerging public health problem. Smith et al.
from Minnesota (10) found that patients infected
with resistant C. jejuni had longer duration of
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       Resistance Mutation
       Macrolide Domain V of 23S rRNA
A2058 → → → → →  G
A2059 → → → → →  G
       Fluoroquinolone gyra → → → → →  Thr - 86
(higher MIC)
Thr - 90
Ala - 70
(lower MIC)
gyra → → → → →  Thr - 86
   +
parc→ → → → →  Arg - 139
(highest MIC)
Figure 1. Macrolide and fluoroquinolone resistance
mechanisms reported in Campylobacter species. For
macrolide resistance, mutations are at either position
shown (Escherichia coli coordinates) in up to all three
copies of ribosomal RNA (14,15, and CA Trieber & DE
Taylor, unpub. data). Fluoroquinolone resistance
depends on a mutation in the quinolone resistance
determining region of DNA gyrase A (GyrA). For
typical MICs see text and references 16-18. The
strains with highest resistance levels had mutations
in both GyrA and topoisomerase IV ParC.
>
>
>
diarrhea than patients with fluoroquinolone-
sensitive isolates. As Campylobacter infections
can be serious in immunocompromised patients,
the identified treatment failure raises the
concern that fluoroquinolone-resistant strains
may increase Campylobacter-associated deaths
in this group of patients.
Mechanism of Macrolide Resistance
in Campylobacter
Erythromycin binds to the ribosome but,
unlike larger macrolides, appears to cause
dissociation of the peptidyl-tRNA, rather than
blocking the peptidyltransferase activity (11).
In  C. jejuni and C. coli, erythromycin
resistance is chromosomally mediated and is due
to alteration of the ribosome (12); the resistance
mechanism is not consistent with presence of an
rRNA methylase, modification of the antibiotic,
or efflux (13). Whole ribosomes or 50S subunits
were purified from erythromycin-resistant strains
and shown to bind much less erythromycin than
ribosomes from sensitive strains. In a closely
related bacterium, Helicobacter pylori, resis-
tance to clarithromycin is due to an alteration of
one of two adenine residues in the 23S rRNA at
the erythromycin-binding site (14). Sequencing
of the 23S rRNA genes from erythromycin-
resistant  Campylobacter spp. identified muta-
tions at these same sites, which are most probably
responsible for resistance (Figure 1) (15).
Mechanism of Fluoroquinolone
Resistance in Campylobacter
Fluoroquinolone resistance in C. jejuni
appears to be due most often to mutations in the
genes encoding subunits of DNA gyrase (gyrA)
and only occasionally to topoisomerase IV (parC)
(Figure 1). DNA gyrase purified from quinolone-
resistant mutants of C. jejuni was 100-fold less
sensitive to inhibition by quinolones than the
wildtype gyrase (19). Cloning and sequencing of
the  C. jejuni  gyrA gene demonstrate that
mutations in gyrA at positions Thr-86, Asp-90,
and Ala-70 were responsible for resistance
(16,17). Mutations at Thr-86 are associated with
higher level resistance to nalidixic acid (MIC 64-
128 µg/mL) and ciprofloxacin (MIC 16-64 µg/mL)
than mutations at Asp-90 or Ala-70. C. jejuni
isolates resistant to even higher levels of
quinolones (ciprofloxacin MIC of 125 µg/mL) carry
two mutations, one in gyrA Thr-86 and the other in
the topoisomerase IV subunit parC at Arg-139 (18).
Evidence of efflux of fluoroquinolones in
C. jejuni (20) also exists. Passage of the bacteria
on pefloxacin-containing agar has led to the
isolation of a fluoroquinolone-resistant strain.
This strain was also resistant to tetracycline,
erythromycin, chloramphenicol, and several  β -
lactams. The pefloxacin-resistant strain carried a
mutation at Thr-86 of gyrA, likely responsible, in
part, for fluoroquinolone resistance. Broad-
specificity efflux pumps in C. jejuni, which cause
fluoroquinolone resistance, have not yet been
shown to be clinically relevant.
Use of Macrolides and
Quinolones in Food Animals
Antibiotics of the macrolide-lincosamide
group have been used in treating food animals
worldwide for several decades. The most
commonly used agents have been lincomycin and
tylosin for controlling dysentery and Myco-
plasma infections in swine and spiramycin for
treating mastitis in cattle. For the past 20 years,
tylosin has also been the most commonly used
agent for growth promotion in swine production
worldwide, whereas spiramycin has been26 Emerging Infectious Diseases Vol. 7, No. 1, January–February 2001
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Table 1. Veterinary licensing of fluoroquinolones in selected countries
Country   Substance Licensing year    Animal species
Austria (22) Enrofloxacin 1992 Cattle, pigs, poultry
Danofloxacin 1996 Poultry
Difloxacin 1998 Poultry
Canadaa Enrofloxacin 1987 (withdrawn in 1997) Turkey (egg dip)
Denmark (22) Enrofloxacin 1991 Cattle, pigs, poultry
Danofloxacin 1993 Poultry
Difloxacin 1998 Poultry, turkey
Marbofloxacin 1998 Cattle, pigs, dogs, cats
Finland (22) Enrofloxacin 1992 (oral use withdrawn Pigs
  in 1999)
Difloxacin 1998 Poultry
France (22) Enrofloxacin 1991 Cattle, poultry
Danofloxacin 1996 Cattle
Marbofloxacin 1993 Cattle
Difloxacin 1998 Poultry
Italy (22) Enrofloxacin 1989 Cattle, pigs, poultry
Difloxacin 1998 Poultry
Japanb Enrofloxacin 1991 Cattle, poultry
1992 Pigs
Danofloxacin 1992 Poultry
1993 Cattle, pigs
Ofloxacin 1992 Poultry
Orbifloxacin 1993 Cattle, pigs
Difloxacin 1996 Pigs
Norfloxacin 1998 Poultry
Netherlands (22) Enrofloxacin 1987 Cattle, pigs, poultry
Difloxacin 1998 Poultry
Spain (22) Enrofloxacin 1986 Cattle, pigs, poultry
Difloxacin 1998 Poultry
United Kingdom (22) Enrofloxacin 1993 Cattle, pigs, poultry
Danofloxacin 1993 Poultry
Marbofloxacin 1995 Cattle
Difloxacin 1998 Poultry
USAc Enrofloxacin Approx. 1987-88 Dogs, cats
1996 Poultry
Sarafloxacin 1999 Cattle
1995 Poultry
aRJ Irwin, Health Canada, 1999. pers. comm.
bY Tamura, National Veterinary Assay Laboratory, Japan, 1999. pers. comm.
cJL Watts. Pharmacia/Upjohn, Kalamazoo, Michigan, 1999. pers. comm.
commonly used in poultry. The use of macrolides
for growth promotion has been banned in all
European Union countries since July 1999.
Several fluoroquinolones are available for
treating food animals, such as poultry, cattle,
pigs, and fish, in many countries. While
information on global use is limited, worldwide
use in food animals was estimated at 120 tons in
1997; use in humans has been estimated at more
than 800 tons (21). Data are available only for the
year of veterinary licensing of fluoroquinolones
by country (Table 1). Licensing for use does not
necessarily mean that the drug is actually used,
so even these data have to be considered with
caution. However, quinolone treatment of
Campylobacter-colonized broiler chickens has
induced quinolone resistance under experimen-
tal conditions (23).
Macrolide and Quinolone Resistance
in Isolates from Food Animals and
Foods of Animal Origin
Campylobacter is carried in the intestinal
tract of wild and domestic animals and, as result27 Vol. 7, No. 1, January–February 2001 Emerging Infectious Diseases
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of fecal contact during processing, frequently
contaminates foods derived from animals.
C. jejuni is predominant in broilers and cattle but
is infrequent in pigs (where C. coli predominates)
(24). In food animals, the prevalence of resistance
to erythromycin is generally higher in C. coli, in
particular in C. coli isolates from pigs, than in
C. jejuni (24-26). In a recent study from Spain
(27), rates of erythromycin and quinolone
resistance in C. coli from pigs were 81% and
100%, respectively. High erythromycin resis-
tance in pigs may be related to extensive
veterinary use of macrolides (5,28).
In food products of animal origin, the
occurrence of Campylobacter is much higher in
poultry than in other categories, e.g., pork or beef
(29). Therefore, Campylobacter resistance data
are primarily based on poultry products,
especially broiler meat. For a number of
countries, fluoroquinolone-resistance rates are
similar in isolates from poultry products and
humans (10,25,27,30-32). In the United King-
dom, enrofloxacin (a derivative of ciprofloxacin)
was first licensed in late 1993; before then,
domestically bred chickens were less fre-
quently infected with quinolone-resistant
campylobacters than imported chicken prod-
ucts. Using a simple model, researchers were
able to correlate the previously observed
resistance percentage in domestically acquired
cases with estimates of the amount of imported
chicken consumed in the United Kingdom (32).
In recent data from Spain and Taiwan, rates of
erythromycin resistance were 17% and 17%,
respectively, in C. jejuni isolated from foods,
whereas for C. coli the figures were 50% and 83%,
respectively (27,31).
Transmission of Resistant Campylobacter
from Animals to Humans
Campylobacteriosis is primarily a zoonosis.
Evidence to indicate that fresh raw meat,
especially poultry, is a major source of infection is
ample, even though other sources such as raw
milk, water, and pets may contribute to human
infection (1,5,33-38).
Studying the transmission of antimicrobial
resistance from animals (especially poultry to
humans) has been difficult because the chain of
transmission is often complex. The number of
macrolide- and fluoroquinolone-resistant iso-
lates from humans is influenced by several
factors including veterinary use of macrolides
(approved for use as antimicrobial growth
promoters or as therapeutic drugs) and
fluoroquinolones (only approved as therapeutic
drugs) at a given location (24,39); association
with recent or current antimicrobial treatment of
patients; the origin of isolates (children vs.
adults; inpatients vs. outpatients); travel (10,40-
45); and sampling strategy and susceptibility
testing procedures (no consensus as to method,
media, culture conditions, or breakpoints [43,46]).
These factors stress the need for cautious
interpretation and comparison of data from
different centers. However, several studies have
shown that food animals can be a substantial
source of infection in humans and that the same
serotypes and genotypes can be isolated from
humans and food animals (29,36,37,47-49). DNA
profiling of Danish C. jejuni serotype O:2 strains
using pulsed-field gel electrophoresis with four
restriction enzymes identified common geno-
types in humans, poultry, cattle and swine (SLW
On, EM Nielsen, and J Engberg, unpub. data).
Typing data on resistant isolates is sparse, but
Smith and colleagues (10) found DNA finger-
prints of quinolone-resistant C. jejuni from U.S.-
produced poultry identical to those of resistant C.
jejuni from domestically acquired infections in
humans. Therefore, the susceptibility of humans
strains originating in animals to antibiotics can
be related to the exposure of animal strains to
antibiotic agents used in farming.
Is There a Link Between Macrolide and
Fluoroquinolone Use in Humans and
Resistant Campylobacter Infections?
Some investigators suggest that resistance in
C. jejuni and C. coli is driven by use of antibiotics
for treating human infections rather than by
veterinary use. Induction of macrolide resistance
during treatment has been reported infrequently
(50). However, induction of macrolide resistance
may play a role in areas with a large reservoir of
asymptomatic Campylobacter carriers and fre-
quent use of macrolides in humans.
Induction of fluoroquinolone resistance
during treatment is well recognized and often
reported (8,51-53). A predicted 10% of patients
treated with a fluoroquinolone for Campylobacter
enteritis harbor quinolone-resistant Campylo-
bacter  strains (6). Recently, Ellis-Pegler (53)
found that fluoroquinolone resistance developed
in 18% to 28% of patients in their prospective
trial. Development of resistance has been28 Emerging Infectious Diseases Vol. 7, No. 1, January–February 2001
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Figure 2. Trends for quinolone resistance rates (in percentages) among Campylobacter coli and C. jejuni combined
from human sources around the world. The bars represent both nalidixic acid and fluoroquinolone resistance and
are based on mean values of resistance from numerous reports (9,17,24,27,39,43,56-58,61-64,72-75,78,88, plus
pers. comm. from Feirel G and Rautelin H, and unpub. data from Nachamkin I).
reported within 24 hrs of treatment, but
prolonged therapy, e.g., in immunosuppressed
patients, is also a risk factor (52,54).
Smith et al. (10) showed that use of a
quinolone before culture accounted for a
maximum of 15% of resistant isolates during
1996 to 1998. In addition, an increasing number
of reports claim that fluoroquinolone-resistant
strains have been isolated from patients who had
not received medical treatment,  suggesting that
strains were already fluoroquinolone resistant
before causing the infection (7,31,32,55-57).
Since human-to-human transmission of C. jejuni
and C. coli is rare (9), patients infected with resis-
tant Campylobacter are not an important source of
resistant Campylobacter for other humans.
Before fluoroquinolones were introduced in
veterinary medicine, they were widely used in
human medicine in a number of countries,
including the Netherlands and the United States
(since 1985 and 1987, respectively), without
emergence of quinolone resistance in
Campylobacter in humans. In contrast, emerging
quinolone resistance in humans often coincides
with or follows the approval of fluoroquinolones
in animal husbandry (Table 1, Figure 2). Thus,
while human macrolide and fluoroquinolone use
contributes to the increase in resistance in
humans, their relative contribution to increase in
resistance compared to the use of these agents in
husbandry appears to be small.
Frequency of Macrolide
Resistance in Human Isolates
Data on erythromycin and azithromycin
resistance in C. jejuni,  C. coli, and the two
organisms combined, isolated from humans
around the world since 1989, differ by country29 Vol. 7, No. 1, January–February 2001 Emerging Infectious Diseases
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Table 2. Erythromycin and azithromycin resistance rates (%) in Campylobacter in humans, worldwide, since 1989
Country C. jejuni C. coli C. jejuni  and C. coli             Reference
Austria   0.7   5.5 <1-1.4 (58 & pers. comm.a)
Canada   0-3.3     -     - (59,60)
Denmark   0 14.0   0-4 (24,61,62)
Finland     -     - <1-3 (43,63, & pers. comm.b)
France   1.1 12.2   3.5 (64)
Hungary     -     -   0 (65)
Italy   1.2-6 16-68.4   7.8-11.6 (66-69)
Japan   0.8     -     - (66)
New Zealand     -     -   1.5 (70)
Singapore     -     - 51 (71)
Spain   0-11.0   0-35.0   3.2-7.3 (17,27,56,57,72)
Sweden   6.4c 11.1c   7.3c (44)
Taiwan 10.0 50.0 18.3 (31)
Thailand   -     -   0-31.0 (73,74)
United Kingdom   1 13   1.8 (75)
United States   0-7.8     -     - (10,76-78, & unpub. datad)
aG Feierl, 2000, pers. comm.
bH Rautelin, 1999, pers. comm.
c90% of isolates were acquired abroad.
dI Nachamkin, 2000, unpub. data.
and species (Table 2). Almost all studies report a
higher frequency of erythromycin resistance in
C. coli than in C. jejuni (0% to 11% in C. jejuni vs.
0% to 68.4% in C. coli). Trends over time for
erythromycin resistance show stable and low
rates in Japan, Canada, and Finland, but recent
development of resistance in Thailand and
Sweden (45,73).
Trends over Time for
Quinolone Resistance
Resistance to fluoroquinolones in
Campylobacter has clearly increased over the
past decade in many parts of the world (Figure 2).
Before 1989, resistance was rare. With the
introduction of enrofloxacin in veterinary
medicine (Table 1) and (probably less important)
fluoroquinolones in human medicine in mainland
Europe (the Netherlands, Finland, France, and
Spain), a rapid emergence of quinolone resis-
tance in Campylobacter isolates from patients
was noted (8,9,43,55,64,89,90).
Surveillance data on resistance rates in
human isolates from Asia soon indicated an equal
increase (84,91). Quinolones were approved for
veterinary use in the United Kingdom and the
United States in late 1993 and 1995, respectively;
reports from these areas now show increasing
quinolone-resistance profiles (10,39,88).
In the latest data from Taiwan, Thailand, and
Spain, rates of fluoroquinolone resistance in
C. jejuni, or C. jejuni and C. coli combined were
56.9%, 84%, and 75% to 88%, respectively
(27,31,40,73). In these regions, where quinolone
resistance is highly endemic and Campylobacter
spp. predominate, fluoroquinolones cannot be
recommended for community-acquired bacterial
diarrhea. Although lower frequencies are re-
ported from other regions, recent trends show a
clear tendency of emerging quinolone resistance
in many countries. Quinolone resistance in
human isolates often coincides with or follows the
approval of fluoroquinolones for use in animal
husbandry (Table 1, Figure 2), although some
differences in resistance rates between countries
may be explained by differences in association
with foreign travel, commerce, methods of
testing, and surveillance activity.
Multidrug Resistance
Multidrug resistance to macrolides and
fluoroquinolones must be considered highly
undesirable in Campylobacter as these two
classes are generally advocated as first- and
second-line drugs for antimicrobial treatment of
Campylobacter enteritis.
Additional resistance to other relevant
therapeutic agents poses a risk when there is no
effective antimicrobial regimen for Campylobacter
infections. Recently, Hoge et al. (73) found 100%
co-resistance between Thai isolates resistant to
azithromycin and ciprofloxacin in the last 2 years30 Emerging Infectious Diseases Vol. 7, No. 1, January–February 2001
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of surveillance. In addition, the level of
tetracycline and ampicillin resistance in Thai-
land is so high that these agents now have no role
in the treatment of Campylobacter or noncholera
diarrhea. Li et al. (31) reported that concomitant
resistance rates among nalidixic acid-resistant
C. jejuni isolates from their patients (exclusively
children) were as follows: gentamicin 2%,
erythromycin 12%, clindamycin 12%, tetracyline
97%, and ciprofloxacin 66%. All of these human
erythromycin-resistant  C. jejuni isolates and
90% of the C. coli isolates were concomitantly
resistant to clindamycin.
Consequences of Resistance for the
Clinical Decision-making Process
Distinguishing infections caused by different
enteric pathogens is seldom possible, so
antimicrobial-drug use in the clinical setting is
not confined to the treatment of Campylobacter
spp. but rather to empiric treatment of
community-acquired diarrhea in general. In-
creased rates of resistance have also been
reported from nontyphoidal salmonellae (25,92),
and documented failures in the treatment of
human  Salmonella infections have been de-
scribed (93). Therefore, having continuous
information on the resistance patterns of the
most common bacteria causing gastrointestinal
infections is critical.
Control Measures
Surveillance of resistance in Campylobacter
is of paramount importance when
fluoroquinolones are used to treat human
infections. Systematic surveillance and timely
reporting of antibiotic resistance patterns in C.
jejuni and C. coli and other enteric pathogens
from different regions should become a high
priority. The principal purpose of monitoring
antimicrobial resistance trends in enteric
pathogens is to provide clinicians with data that
can be used to select appropriate treatment
regimens. Surveillance should emphasize antibi-
otics that are being used routinely to treat
diarrhea, as well as any alternatives, such as
fluoroquinolones, macrolides, and gentamicin.
Equally important is the accessibility of the data
to those providing primary care. For quinolones,
quantitative nalidixic acid susceptibility data are
more sensitive than fluoroquinolone susceptibil-
ity data for detecting common first-step
mutations causing reduced susceptibility.
To circumvent the development of resistance,
we have two options: infection control (zoonoses
control) and prudent use of antibiotics. Improved
infection control strategies along the chain
“stable to the table” and guidelines for prudent
use of antimicrobial agents in food animal
production should be developed (94,95). To
prevent further development of resistance in
Campylobacter, limiting the use of macrolides
and fluoroquinolones for food animals as much as
possible is recommended. In Denmark,
fluoroquinolones are not essential for treatment
of any type of infection in food animals, according
to surveillance performed by the Danish
Veterinary Laboratory, and their use is only
recommended on the rare occasion when no other
therapeutic option is available (22). Because of
the selection for resistance, the use of macrolides
for growth promotion has been banned in all
European Union countries since July 1999. The
effect on the occurrence of resistance in bacteria
in food animals is still not known. However,
preliminary results suggest that macrolide
resistance in C. coli from pigs in Denmark has
decreased along with the decreased use of tylosin
(FM Aarestrup, unpub. data).
Conclusions
Review of in vitro macrolide and quinolone
resistance prevalence and trends in
Campylobacter isolated from humans showed a
temporal relationship between use of quinolones
in food animals and resistant Campylobacter
isolates in humans. The public health effects of
antibiotic use in agricultural practice, including
resistance of C. jejuni and C. coli to macrolides
and quinolones, should be estimated. Adequate
actions for control are strongly needed in both
veterinary and human medicine. The public
health issue of resistance in Campylobacter has
global dimensions because of ever-increasing
international trade and travel.
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